

Document responsible: Siv Lise Bedringaas and Bård Sværi

Document owner: Ørjan Hauge

Valid from: 01.05.2019


Version: 1

Organizational placement: Faculty of

Medicine

Signature:

SOP for immediate action and follow-up of puncture and cut injuries in case of exposure to biological factors



The purpose of this procedure is to prevent / reduce the development of disease when an employee has been exposed to biological factors. The procedure is to ensure that employees and managers are familiar with procedures for measures and treatment in the event of stabs and cuts.

All employees are obliged to familiarize themselves with the procedure and to help when injury occurs.

1. Contents

2.	Gen	eral (Overview	3
	2.1	This	procedure applies to	3
	2.2	Chai	nges from last version	3
	2.3	Abb	reviations	3
	2.4	Defi	nitions	3
	2.5	Forn	ns belonging to the procedure	3
3.	Role	es and	d responsibilities	4
4.	Prev	/enta	tive measures	5
	4.1	Vaco	cine status and vaccination	5
	4.2	lmm	nunosuppressive treatment	5
	4.3	Risk	assessment of own work	5
	4.4	Wor	king alone	5
5.	Prod	cedur	e following an injury	6
	5.1	Perf	orm first aid	6
	5.2	Perf	orm blood tests	6
	5.2.	1	Employee who is injured	6
	5.2.	2	Source person: Patient / donor	7
	5.3	Asse	essment of the source of infection, risk and treatment	7
	5.4	Trea	atment	8
	5.4.	1	In case of a probable infection:	8
	5.4.	2	For known hepatitis B or hepatitis C infection:	8
	5.4.	3	At risk for HIV / retrovirus exposure:	8
	5.5	Foll	ow-up	8
	5.5.	1	Follow-up from BHT	8
	5.5.	2	Follow-up from the department	9
	5.6	Rep	orting	9
	5.7	Flow	v sheet	10
6.	Арр	endix	<	11
	6.1	Risk	of transmission of infection	11
	6.1.	1	Risk of transmission of infection by contact with body fluids	11

SOP for immediate action and follow-up of puncture and cut injuries in case of exposure to biological factors By Siv Lise Bedringaas, Bård Sværi, Gunvor Røssland Landro, Bente Lise Lillebø og Stein Inge Stigen for The Faculty of Medicine and the section for HSE, preparedness and BHT, University of Bergen

with work on gene-modified m		Risk of transmission of infection using Retroviral / Lentiviral vectors (viruses) in connectrk on gene-modified microorganisms (GMM)	
		Risk of transmission of infection following working with human pathogenic bacteria an 12	ıd
6.	1.4	Risk of transmission of infection when working with cell lines	12
6.	1.5	Risk of infection when working with research animals (mice and rats)	12
6.2	Law	s and regulations	13
6.3	Link	KS	13
6.4	App	pendix	14
6.	4.1	Requisition for blood sample to be taken	14
6.	4.2	Consent form for blood sample	15
6.	4.3	Self-declaration form	16
6.	4.4	Occupational injury form, page 1	17

2. General Overview

2.1 This procedure applies to

- Department of Biomedicine
- Clinical Institute 1
- Clinical Institute 2
- Occupational Health Service (BHT)

2.2 Changes from last version

This is the first version

2.3 Abbreviations

GMM	Genetically Modified Microorganisms
ВНТ	Occupational Health Service
MBF	Medical Biochemistry and Pharmacology (Formerly LKB)
LKB	Clinical Biochemistry Laboratory

2.4 Definitions

"0"-test sample	Blood sample taken to determine status less than 48 hours after the incident. This is the starting reference point for further testing.
Organism	Cell, bacterium, virus, human, animal etc.
Source person	A person who has donated blood or other bodily fluid

2.5 Forms belonging to the procedure

Our department has a plastic pocket at the SafetyZone in the 5th, 6th and 7th floor containing the necessary documentation to be used following stabs and cut wounds where there is a risk of exposure to biological factors. Contact: Emil Hausvik, 55 58 60 41 emil.hausvik@uib.no or Bård Sværi, 55 58 68 32, Bard.Svari@uib.no.

The plastic pocket contains:

• Requisition form for MFB / Emergency Medical Department

SOP for immediate action and follow-up of puncture and cut injuries in case of exposure to biological factors By Siv Lise Bedringaas, Bård Sværi, Gunvor Røssland Landro, Bente Lise Lillebø og Stein Inge Stigen for The Faculty of Medicine and the section for HSE, preparedness and BHT, University of Bergen Version 1_ 30.04.19 Page 3 of 17

- Self-Declaration form
- Injury form (to be filled in for NAV)

3. Roles and responsibilities

Role	Responsibility / Task
HSE-coordinator at the department	 Contact with BHT Ensure that all forms are always updated at the department Provide training
Occupational physician / Nurse	 Sign requisitions Perform / participate in risk assessment of infection Follow-up the injured person
Employer	Report the accident / injury to NAVFollow-up the injured person
Injured employee	 Perform first aid Fill in self-declaration form Provide the "0" blood sample Contact the BHT and the immediate supervisor Report HSE nonconformities Complete the occupational injury form to be sent to NAV if a doctor is contacted Follow BHT's suggestions and recommendations
Employee	 Acquire knowledge of the nature of the procedure Provide help in case of accident / injury
Blood sample reception at the hospital (MBF) Weekdays Kl. 08.00 -15.00	Take the "0"-blood sampleSend the results to BHT
"Legen på Høyden" Weekdays Kl. 08.00 -15.00	 Take the "0"-blood sample Send the results to BHT Conduct risk assessment Commence any treatment
Emergency Medical Service (Legevakten) After kl. 15.00 Weekend / Holidays On-duty physician responsible	 Take the "0"-blood sample Send the results to BHT Conduct risk assessment Commence any treatment Start any treatment
for infectious disease	Hospitalization in case of serious risk of infection

4. Preventative measures

4.1 Vaccine status and vaccination

Everyone who works with blood / blood products and/or microorganisms must check their own vaccine status.

Vaccine status can be checked here: https://helsenorge.no/vaksiner/mine-vaksiner

All who potentially can be exposed to infection should be offered vaccination. Although vaccination is a voluntary offer, in some cases the employer may order compulsory vaccination.

Employees who are not vaccinated against hepatitis B should do so by contacting BHT (see 5.2). Employees who work with other pathogens should vaccinate themselves if such a vaccine is available.

4.2 Immunosuppressive treatment

It is recommended that people under immunosuppressive therapy should not work with biological factors.

4.3 Risk assessment of own work

- The working operations must be risk-assessed.
- All workers should have the necessary knowledge of the various biological factors they can come into contact with through their work.

It is recommended that one has a comprehensive overview of information on all cell lines/microorganisms used in the laboratory.

4.4 Working alone

Work where there is a potential risk of serious infection should be avoided outside normal working hours.

If this cannot be avoided, then the employee must have discussed the situation with their immediate superior. Together they must find a satisfactory working solution, for example:

- The timing of the operation if pre-determined
- A colleague is nearby
- A mobile telephone or other way of notification must be readily available

SOP for immediate action and follow-up of puncture and cut injuries in case of exposure to biological factors By Siv Lise Bedringaas, Bård Sværi, Gunvor Røssland Landro, Bente Lise Lillebø og Stein Inge Stigen for The Faculty of Medicine and the section for HSE, preparedness and BHT, University of Bergen Version 1 30.04.19 Page 5 of 17

• The manager is notified when the work is done

See also: Working alone in hazardous working environment

5. Procedure following an injury

This procedure applies in cases where an employee has a cut or puncture wound which may have been exposed to a biological factor, such as a blood product, cell line or microorganisms.



In the event of a stab or cut injury where there is no risk of exposure, perform regular first aid and contact the emergency services if the injury requires treatment by a physician.


5.1 Perform first aid

- Following stab wounds/cuts, allow wounds to bleed, but to not induce bleeding.
- Immediately flush the exposed area with plenty of water for at least 10 minutes.
- In case of spillage of infectious material, disinfect the area with for example Chlorhexidine or Pyrisept for 3-4 minutes.
- Protect the wound with a patch or bandage.
- Obtain the folder containing the self-declaration form.
- Fill out the form (may be done later, but must be completed before the onset of medical treatment)

5.2 Perform blood tests

5.2.1 Employee who is injured

The injured person must provide a "0" blood sample as soon as possible and no later than 48 hours after the incident has occurred to determine the





When	Site	Task/responsibility	Location
Weekdays Kl. 08.00 - 15.00	Blood sample reception at the hospital (MBF)	Take the "0"-blood sampleSend results to BHT	2. floor HUS by the escalator
Weekdays Kl. 08.00 - 15.00	Legene på høyden (alternative)	Take the "0"- blood sample	<u>Christies gate 13</u> (Entrance 1. floor)

SOP for immediate action and follow-up of puncture and cut injuries in case of exposure to biological factors By Siv Lise Bedringaas, Bård Sværi, Gunvor Røssland Landro, Bente Lise Lillebø og Stein Inge Stigen for The Faculty of Medicine and the section for HSE, preparedness and BHT, University of Bergen Version 1 30.04.19 Page 6 of 17



	Must be contacted before 14.00.	 Send results to BHT Conduct risk assessment 	Tlf: 52 69 51 51
After kl. 15.00 Weekend Holiday	Emergency Medical Service (Legevakten)	 Take the "0"- blood sample Send results to BHT Conduct risk assessment 	Solheimsgaten 9. Tlf: 55 56 87 60

- Remember to bring the forms from the folder to the blood sample site / doctor (see 2.5). The requisition form is necessary to have the blood sample taken and get a consultation.
- Blood samples can be taken at Blood sample reception at the hospital (MBF) 2.floor, at Legene på høyden or at Legevakten.
- Fill out the self-declaration form (can be done later, but must be done before contact with a doctor or the BHT).
- Fill out electronic HSE-non-conformity (https://avvik.app.uib.no).

5.2.2 Source person: Patient / donor

If possible, it is an advantage to obtain a sample from the patient (the potential source of infection). Consent is obtained from the patient/ next of kin if this has not already been obtained. The patient must have a blood sample taken at Haukeland University Hospital, Blood sample reception at the hospital (MBF) second floor. The requisition form must contain the personal data of the injured individual involved and the date of injury.

5.3 Assessment of the source of infection, risk and treatment

Following exposure to blood, body fluids or other biological factors, preventative treatment should be considered when:

- The source of infection is a carrier of a human pathogenic organism against which the injured person is not vaccinated
- The source of infection is lentiviral / retroviral vectors (viruses) in connection with GMM work
- The source of infection is a laboratory animal
- The assessment indicates a high risk
- The source of infection is unknown

If the risk assessment indicates a high risk of infection, the employee / colleague should:

- > Contact BHT as soon as possible
- Report to your PI and head of department / department management

SOP for immediate action and follow-up of puncture and cut injuries in case of exposure to biological factors By Siv Lise Bedringaas, Bård Sværi, Gunvor Røssland Landro, Bente Lise Lillebø og Stein Inge Stigen for The Faculty of Medicine and the section for HSE, preparedness and BHT, University of Bergen Version 1 30.04.19 Page 7 of 17

5.4 Treatment

In order to ensure the best possible assessment, it is important that the doctor receives detailed information about the source of infection. It is therefore necessary that the self-declaration form is completed, and that the vaccine status of the injured person is known.



5.4.1 In case of a probable infection:

BHT: Contact BHT for further evaluation if the blood test is taken by the MFB.

- Business Nurse: **55 58 87 42** E-mail: Gunvor.Landro@uib.no
- For more telephone numbers, see: https://www.uib.no/hms-portalen/111462/kontakt-bedriftshelsetjenesten

The Emergency Department (Legevakten): If the "0"-blood sample is taken at the emergency department, any treatment is assessed there. Tel: 55 56 87 60

5.4.2 For known **hepatitis B** or **hepatitis C** infection:

Contact the Emergency Department or Legene på Høyden immediately.

5.4.3 At risk for **HIV / retrovirus** exposure:

Immediately contact Haukeland University Hospital tel. 05300, and ask to speak to the oncall infections doctor.

Preventative treatment should be started within 4 hours and no later than 48 hours.

5.5 Follow-up

BHT and the department are responsible for further follow-up. The process depending on the type of exposure the employee has been subject to.



5.5.1 Follow-up from BHT

All inquiries to BHT and test answer will be sent directly to the BHT doctor who follows up cases with risk of transmission of infection. The occupational health service calls for further follow-up. It is

SOP for immediate action and follow-up of puncture and cut injuries in case of exposure to biological factors By Siv Lise Bedringaas, Bård Sværi, Gunvor Røssland Landro, Bente Lise Lillebø og Stein Inge Stigen for The Faculty of Medicine and the section for HSE, preparedness and BHT, University of Bergen Version 1 30.04.19 Page 8 of 17

important to attend the follow-up appointment to which you are called to attend, so that any necessary measures can be implemented.

5.5.2 Follow-up from the department

The Head of Administration assists in completing and sending a claim form to NAV and takes care of the employee in case of any sick leave or other needs in connection with the injury incurred.

5.6 Reporting

Notify as soon as possible:

- BHT 55 58 87 42 Gunvor Røssland Landro. Email: Gunvor.Landro@uib.no
 - o https://www.uib.no/hms-portalen/111462/kontakt-bedriftshelsetjenesten
- Your PI / Head of Administration / HSE-coordinator

Fill out and submit the following form:

- The HSE nonconformity form (https://avvik.app.uib.no/apex/f?p=692:1
- NAV's occupational injury form is completed together with the Head of administration if a blood sample has been taken.
 - https://www.nav.no/no/Bedrift/Tjenester+og+skjemaer/Meld+yrkesskade+og+yrkessykdom

5.7 Flow sheet







Perform necessary first aid:

- Rinse extensively with water
- Disinfect
- Apply bandages





- Fill out self-declaration form
- Immediately contact supervisor/Head of administration
- Report HSE-nonconformity

Obtain folder with required documents



- Take «0»-blood sample
- Evaluate any risk of the injury with the responsible doctor



Receive preventative treatment if necessary



- Report HSEnonconformity if not previously completed
- Fill in the form to NAV together with the Head of administration



Follow-up at the BHT and with the Head of administration

6. Appendix

6.1 Risk of transmission of infection

6.1.1 Risk of transmission of infection by contact with body fluids¹

The risk of transmission is related to the degree of contact with blood of other body fluids. There is no risk of transmission through contact with blood on intact skin. Skin-puncture injuries are considered the most common form of transmission of infection.

There is a risk of transmission of infection by contamination of a contaminated cannula

- Hepatitis B 10 30 %
- Hepatitis C 5 5 %
- HIV approx. 0.3% In the Nordic countries, transmission of HIV has never been proven following puncture damage.

In Norway, the prevalence of Hepatitis B and C is greatest among injecting drug users. The prevalence of HIV-positive is greatest among people from Africa and Southeast Asia. There has been an increase in infection among homosexuals in recent years, while for injecting addicts there is little chance of new infection. Therefore, the chance that a patient is infected with Hepatitis B, C or HIV will be low as long as he/she does not belong to one of these risk groups.

6.1.2 Risk of transmission of infection using Retroviral / Lentiviral vectors (viruses) in connection with work on gene-modified microorganisms (GMM)

A stab wound/ cutaneous injury is the highest risk factor for transmission of infection when working with Lentiviral vectors in the laboratory. The other type of exposure hazard is from airborne aerosols via the respiratory tract, partly due to spills or too much pipetting.

Exposure can lead to one-off infections with the transmission of viral genetic material that can result in:

- Mutations
- Development of oncogenesis
- Generation of replication competent lentivirus (RKL)

¹ Norwegian Institute of Public Health: http://www.uib.no/fg/dyreavdelingen/66095/kontroll-med-smitte-patogener-og-mikrobiell-status

6.1.3 Risk of transmission of infection following working with human pathogenic bacteria and viruses

Transmission of infection by stab-wounds and cut injuries by direct exposure to bacteria and viruses is considered high. Exposure risk depends on the type of pathogen and this must be evaluated for each type.

6.1.4 Risk of transmission of infection when working with cell lines

The greatest risk of exposure when working with cell lines is the presence of pathogenic agents. Commercially available cell lines have been tested for a range of potential pathogenic viruses and bacteria. Cell lines infected with agents that can induce moderate disease are marked with a higher risk level (BSL 2). Cell line providers recommend that all cell lines, although labelled as BSL 1, be treated as potential carrier at the BSL 2 level, as they cannot test for all types of viruses and bacteria.

The closer the genetic similarity the cell line has to human cells, the higher risk of transmission of infection. This is due to the relationship of the host and the human immunological response factors. Human cell lines therefore pose the greatest risk. Other factors that also need to be considered are the concentration of cells and the number of cell lines one has been exposed to.

The risk of transmission of cells from human or other animal species is considered minimal.

6.1.5 Risk of infection when working with research animals (mice and rats)

Infectious material can be transmitted following skin damage, via the respiratory tract or by means of using aerosols for example, during cleaning cages or the animals' own activity. Infection can also be transmitted through surgery and dissection.

Possible exposure hazards:

- Development of allergy to test animals
- Zoonoses (infectious diseases that can be latent in the experimental animal. Some of these can be very dangerous for humans.)
- Injection of material meant for injection into a test animal (e.g. cancer cells, cytostatic drugs, other agents used for treatment)

6.2 Laws and regulations

The Working Environment Act § 4-5	Especially regarding chemical and biological health hazards
Internal control regulations § 5 paragraph 6	Reduce risk conditions
Regulations on the execution of work Chapter 6 § 31-3	Work environments that may cause exposure to biological factors. Registration of workers using biological factors.
Regulations on reorganizing and participation chapters. 7-11, 13	Risk assessment, training, information, planning, facilitation, work instructions, company health service, reporting obligation and protective equipment.
Workplace regulations chapters. 5 and 8	Signs, marking/labelling of possible exposure to biological factors
Contingency Protection Act § 3-2 and § 6-1	(Prior) survey of employees and students
National Insurance Act Chapter. 13	Occupational injury coverage

6.3 Links

BHT, contact info	https://www.uib.no/hms-portalen/111462/kontakt-
	<u>bedriftshelsetjenesten</u>
First aid	https://www.uib.no/hms-portalen/74267/f%C3%B8rstehjelp
HSE deviation reports	https://avvik.app.uib.no/apex/f?p=692:1
NAV occupational injury form	https://www.nav.no/no/Bedrift/Tjenester+og+skjemaer/Meld+yrkesskade+og+yrkessykdom

6.4 Appendix

6.4.1 Requisition for blood sample to be taken

There are two forms, one for the injured worker and one concerning the source of infection (if relevant).

NB! When obtaining a blood sample from the source person, remember the consent form.

0							
HELSE BEI		Chadataaaatt					
Postboks 1400, 502	1 Bergen	Skadet ansatt					
	The state of the s	Fødselsnr	UT				
MIKROBIOLOGISK AVDEL TLF: 55 97 47 00	ING (MIA)	Navn					
AVD. FOR IMMUNOLOGI O	G TRANSFUSIONSMEDISIN	Navi					
TLF: 55 97 46 38		Adresse		• • HELSE			
Rekvirentkode	Stein-Inge Stigen	Automo		 Haukeland u 	niversitetssjukehus	kildeperson	
Rekvirentens navn	Bedr. lege	Poststed	Dr. D.		0, 5021 Bergen	Fødselanr	on the
og adresse Ur	ilversitetet i Bergen	rosisied	Kvinne Mann	MIKROBIOLOGISK AT TLF: 55 97 47 00	/DELING (MIA)	Navn	YLL UT
	HMS-Seksjonen	Betales av		AVD, FOR IMMUNOLO	GI OG TRANSFUSJONSMEDISIN	reavit	
PE	. 7800, 5020 Bergen	☐ Trygdekontor ☐ Instit	usjon Bedrift	TLF: 55 97 46 38	120000 pp.	Adresse	
	TII. 55 58 20 54	Proven tatt dato	М	Rekvirentkode	Stein-Inge Stigen		
		17001000000	N.	Rekvirentens navn og adresse	Bedr. lege Universitetet i Bergen	Poststed	☐ Kvinne ☐ Mann
Klinisk problemstilling: Id	I-nr. 8335.869	Prøvetaker		og auresse	HMS-Seksionen	Betoles av	
					Pb. 7800, 5020 Bergen	☐ Trygdekontor [Institusion Bedrift
0-prøve pga stikk- og el	las livitalis da				TII. 55 58 20 54	Proven tatt dato	И
u-prøve pga sukk- og ei	ier kullskade.						M.
Skadedato:	= 8	☐ Kopi ønskes til:		Klinisk problemstilling:	ld-nr. 8335.869	Prøvetaker	
PRØVER TIL MIKROBIOLOG Antimikrobiell behandling:	GISK AVDELING			0-prøve pga stikk- o	g eller kuttskade. Kildeperson.		
		Vaksinasjon:	Gravid? 🛮 Ja 🔻 Nei	Skaddes initialer:	. skadedato:	☐ Kopi daskes til :	
Urin til bakterlologisk dyrkning ☐ Midtstråle ☐ Engan	Annet provemateriale		ngsprøver	# 1 - CAMPA TO A A A A A A A A A A A A A A A A A A		Li Kopi gaskes til :	
	gskateler	kret Abscessmateriale Tar	mpatogene bakterier stridium difficile toxin	PRØVER TIL MIKROBI Antimikrobiell behandling:	DLOGISK AVDELING	100000000000000000000000000000000000000	
Asymptomatisk bakteriuri hos gn	avid DEGGVESSE DAM	U Clo				Vuksinasjon:	Gravid?
Luftvelsprøver	☐ Bakteriologisk dy.	kning	avirus/Adenovirus	Urin til bakteriologisk dyrk Midtstrile	nling Annet provensaterio Engangikuteter		Avforingsprøver
☐ Halssekret ☐ Nesesekret ☐ Nas ☐ Øresekret ☐ Annet materiale	sofarynkssekret Herpes simplex vi	rus 🗆 Pari	sitter	Posepretve, barn	Pennanent kateter	kmoet materiale	Thrmpstogene bakterier Clostridium difficile toxin
Spiesesser Li Annet materiale	Usricella zoster vi ☐ Enterovirus	rus 🗆 Hel	cobacter pylori Annet	☐ Asymptomatisk bakteriori Luftvelsprøver	hos gravid		☐ Norovirus
☐ Influensavirus PCR	☐ Adenovirus		ulosediagnostikk	☐ Halssekret ☐ Nesesekret	☐ Bakteriologisk ☐ Nasofarynkssekret ☐ Herpes simplex	dyrkning virus	Rotavirus/Adenovirus Parasitter
Bordetella pertussis PCR	Seksuelt overførbare s		pektorat Urin	☐ Øresekret ☐ Annet mate	iale Varicella zoster		☐ Helicobacter pylori ☐ Annet
Mycoplasma paeumoniae PCR	☐ Urin ☐ Vaginalse	KIEL LI CELVIXSERIEL	et materiale	☐ Influensavirus PCR	Enterorirus Adenovirus		Tuberkulesediagnostikk
Chlamydophila pneumoniae PC Resp.syncyt.virus PCR	Urethrasekret Annet materiale		underspleelser	☐ Bordetella pertussis PCF	Sekszelt overferbary		☐ Ekspektorat ☐ Urin
Humant metapneumovirus PCR		kker		Mycoplasma pneumonia Chlamydophila pneumonia	e PCR Urin Vagina lae PCR Urethrasekret	lockret Cervixsekret	MRSA-underuskelser
Parainfluensavirus PCR	☐ Klamydia	ПАпп	et materiale	☐ Resp. syncyt virus PCR	☐ Annet moteriale		MRSA-underugkelser Nesebor Svelg/Tossiller
Parotittvirus PCR (kusma)	Mycoplasma genit	dium (kun urin)		Humant metapneumovin	is PCR Klamydia/Gono	kokker	Perineum
Bakteriologisk dyrkning Blodprøver	Genital herpes (ku			Perainflutosarirus PCR Parotittrirus PCR (kusm		nitelium (fron mie)	Annet materiale
s Bordetella pertussis	s Herpes simplex virus s Varicella zoster virus	s Toxoplasmose	s Hepatitt A-antistoff IgG	☐ Bakteriologisk dyrkning	☐ Genital herpes (kwn sekret)	
s Mycoplasma pneumoniae	s Meslingevirus	s Syfilis s Borrelia	s Hepatitt A-antistoff IgM S Hepatitt Bs-antistoff	Blodprøver Blodprøver Blodprøver	s Herpes simplex virus	s Toxoplasmose	☐s Hepatitt A-antistoff IgG
s Chlamydophila pneumoniae	s Parotittvirus	s Svangerskapsanalyser (INMA Spin-	(IIV) S Hepatitt Bs-antistoff (IIV) S Hepatitt Bs-antigen	s Mycoplasma pneumoniae	s Varicello zoster virus s Mexlingevirus	□s Syfilis □s Borrelia	s Hepatitt A-antistoff IgM s Hepatitt Bs-antistoff
s Epstein-Barr virus s Cytomegalovirus	s Rubeltavirus	s Assistert befruktning (donor)	S Hepatitt B core-antistoff IgG	s Chlamydophila pneumonia	e s Parotinvirus	s Svangenkapsanalyser a	No. 100 No. Heroditt Bu-ordigen
Lis Cytomegatovirus	☐s Parvovirus B19	☐s Annet	N's Henatitt C-antistoff	s Epstein-Borr virus s Cytomegalovirus	s Rubellavirus Is Parvovirus B19	s Assistert befruktning (d	onor) As Hepatist B core-antisteff IgG
PRØVER TIL AVDELING FOR I	IMMUNOLOGI OG TRANSFUSJON	s Hepatist C virus PCR (eget gel	str) 🏿 s HIV			The Honotin C view BCD (eget gelrar) Ns HIV
Auteantistoff	Antistoff	Immunglobuliner	Komplement	PRØVER TIL AVDELING	FOR IMMUNOLOGI OG TRANSFUSJO	ONSMEDISIN	
☐s ANCA	□s AST	□s □sp lgG	□s C3, C4	Autenntistoff s ANCA	Antistoff S AST	Immunglobuliner sp lgG	Kemplement
s Glomerulus-basalmembran	s Anti DNase B	□s IgA	□s CI-INH	s Glomerulus-basalmembras	a Anti DNese B	□s □sp IgG □s IgA	□s C3, C4 □s C1-INH
s ANA med spesifisiteter s Glatt muskulatur	s Pneumokokkvaksine	□s □sp IgM	s Komplementfunksjonstest	s ANA med spesifisiteter	s Pasumokoldevalerine	□s □sp IsM	s Komplementfunksjonstest
s Mitokondrier	s Difteri/tetanusvaksine	s Sp u Agarose-el forese S M-komponent kvantitering	Vevstyping	☐s Mitokondrier	s Difteri/tetanusvaksine	s Sp u Agarose-elf	
s Parietalceller		s Kuldeagglutininer v/+37°C	□ eb HLA-B27 Bechterew □ eb HLA-DRIDQ collakiass	□ = Parietalceller		s Kuldeagglufininer vf+3	S7°C Geb HLA-DRIDO collinkiore
s Intrinsisk faktor	Reumatold faktor	S Kryoglobuliner v/+37°C	Immunfenotyping	s Intrinsisk faktor s Kardiolipin, fonfolipid	Reumatold faktor Is Latex RFtest	☐s Kryoglobuliner v/+2	7°C Immunfenetyping
s Kardiolipin, fosfolipid	s Latex RFtest	□s IgD	□eb CD4/CD8-kvantitering	☐s LKM1, LeverNyreMikrose		sk Spinalvæskespesifikt p	cb CD4/CD8-kvantitering
s LKM1, LeverNyreMikrosom. ag	□s Anti-CCP	sk Spinalvæskespesifikt protein	□ cb Lymfocytt-kvantitering	s Celiakiantisteff	T. (2000)	0.	Deb CD34-krentiterine
as community			□ eb CD34-kvantitering			Os	Utridet immunfenotsning se bat
analyzer skroyel med uthanet	rever spesielle forholdsregler. Se baksiden.		Utvidet immunfenotyping se bak	Analyser skrevet med utheret si	riff krever spesielle forholdsregler. Se baksid	en. s = serum eb = EDTA-blod	ep = EDTA-plasma u = urin sk = sekret.
major sarete med timere ikriji ki	ever spesiene fornoidsregier. Se baksiden.	s = serum et = EDTA-blod ep = ED	TA-plasma u = urin sk = sekret.				



Samtykkeskjema for blodprøve

Samtykke til blodprøve	
	ller annen kroppsvæske til forskning, har den som har ller kutt som gir grunnlag for at det kan tas blodprøve
Jeg samtykker til at det blir tatt blodprøve blodprøven skal kun brukes til å sjekke sta	e, eller at tidligere blodprøve kan brukes. Denne atus for hepatitt B, hepatitt C og HIV.
Navn:	
Dato / underskrift <u>pasient/kildeperson</u>	Dato / underskrift <u>behandler</u>

Samtyldæskjema tilhørende SOP for oppfølging av stikk og kutt skader ved fare for eksponering av biologiske faktorer. Det medisinske fakultet, Universitetet i Bergen

Egenerklæringsskjema ved stikk og kuttskader

Navn:	Enhet:
Vaksinestatus: Hepatitt B	Tetanus
TYPE ARBEID	BESKRIV TYPE EKSPONERING
BLOD OG KROPPSVÆSKER	Blod Annen kroppsvæske:
	Kjent infeksjon hos pasient:
RETROVIRALE VEKTORER (GMM)	Vektor/- system:
	Type geninnlegg:
	Mutert Ikke mutert
	Genets Opprinnelse: Humant
	Genets funksjon:
	Mottaker organisme:
HUMAN PATOGENE BAKTERIER OG VIRUS	Navn:
	Type: Bakterie Virus Annet:
	Sykdom:
CELLELINJER	N
	Navn: Human
	Vevstype: Celletype:
	Sykdom:
VÆSKE FRA FORSØKSDYR	Mus Rotte Annet:
	Injisert organisme: Human
	Celletype:Sykdom:
	Genetisk mutasjon:
	Kjent infeksjon hos forsøksdyret:
Egeneridæringsskjema tilhørende S	• OP for oppfølging av stikk og kutt skader ved fare for eksponering av biologiske

Det medisinske fakultet, Universitetet i Bergen

SOP for immediate action and follow-up of puncture and cut injuries in case of exposure to biological factors By Siv Lise Bedringaas, Bård Sværi, Gunvor Røssland Landro, Bente Lise Lillebø og Stein Inge Stigen for The Faculty of Medicine and the section for HSE, preparedness and BHT, University of Bergen Version 1_ 30.04.19 Page 16 of 17

Versjon 1_ 30.04.19

		nelderen sende	NAV,	påfør	t under	rrkesskade e arbeid på no indterritoriu	rsk eller	,
1 Opplysnir	nger om d	len skadede o	og arbeidets ar	t				
Den skadedes fullstendige etternavn og fornavn					orgerskap		Fødselsnummer (11 siffer)	
Bostedsadresse eller oppholdsadresse i Norge Husn					Sted		Bosteds-/oppholdskommun	
Stilling (tittel)	Da ulykken ir	nntraff eller da skad	lelig påvirkning fant st	ed: Yn	e (fagfelt)	Stillingsprosent	fra Arbeidsfo	rholdet vart
Kompetanse- nivå 10-årig grunn- skole	1-3 år på videre- gående skoles nivå	utover videre- gående skoles niva	g Universitet/høy- skoleutdanning med varighet 4 år eller mer	Arbeid	la skadelig	rhold da ulykken påvirkning fant : Selvstendig nærings- drivende	sted fril	ris selvsten anser, frivill kesskadetry Ja
	_	rbeidsgivere					Omanicaciones	u immor
Anemagiver da	Arbeidsgiver da ulykken inntraff eller da skadelig påvirkning fant sted						Organisasjonsnummer	
Vei-/gatenavn			Husnr.	Postnr.	Sted		Telefonnummer	
Fant ulykken ste	ed på	Ja Nei	Hvis nei, oppgi	hvor (me	d nøyaktig	adresse)		1 1
ovenstående ad	resse?			ببب				
Lov om yrkessk	agetorsikring.	Arbeidsgiverens to	rsikringsselskap: Navr	og adre	sse			
3 Ulvkke - o	pplysnin	ger ved arbei	dsulvkke T				r det ønskelig a	
Ulykkesdato		eslett Arbeidstidso		Annet	Ulykken	I normal	må oppgi den v Under over-	Ut <u>enfo</u> r arb
		Bare da	gtid (06.00-21.00)		inntraff:	arbeidstid	tidsarb	
Lønnsform da ulykken skjedde		nn/fast lønn sjons/akkord	På vanlig arbeidsplass?	Ja	Nei	Inne Ute	På vei til/fra arbeidet?	Ja 1
På vei mellom arbeidssteder?	Ja Nei		Meldt arbeids- tilsynet?	Ja	Nei	Hadde skadede i for å utføre arb.o		Ja I
	ulykke		Bakgrunn	(2)	C Skad		1 0 1	t kropps
Oppgi kode (eve	orienteringer entuelt flere)	Oder-	se orienteringen (eventuelt flere)		der - se o kode (ever	ienteringen tuelt flere)	Oppgi kode (ev	entuelt flere
<u>▼</u> <u>▼</u>		<u> </u>	<u> </u>	-		<u> </u>	<u> </u>	
F Type arbeidsplass oder - se orienteringen				2	G Av der - se o	rvik rienteringen	H Antatt fravær	
oppgi kode (eve		Oppgi kode	(eventuelt flere)		kode (ever		oppgi kode	
			<u> </u>		▼	<u> </u>		
Gi nærmere	beskrivelse	av hendelsesf	orløpet og av skad	den i fe	lt 5 nede	nfor		
			tanke om sykd					
		om mulig diagnose	•		ivist (dag, r		Død av yrkes- sykdommen?	Ja 1
Påvirkning som	fremkalte syk	dommen (f eks stei	nstøv, asbest, løsemid	ler, andr	e kjemiske	stoffer, vibrasjone	r, larm)	
Varighet av påvi	rkningen (fom	måned.år). Hvis fle	ere perioder, oppgi alle	. Hva be	estod arbei	det i da påvirkning	en fant sted?	
5 Utfyllende	heskrive	olse		Lini				
Nærmere beskri Oppgi navn og a	ivelse av hend adresse på ev	delsesforløpet, utløs entuelle vitner. Hvis	sende og bakenforligg s du har kjennskap til d deg oppgi navn og ad	m arbeid	istakeren h	ar blitt undersøkt/l	fått behandling i f	forbindelse

https://www.nav.no/no/Bedrift/Tjenester+og+skjemaer/Meld+yrkesskade+og+yrkessykdom

SOP for immediate action and follow-up of puncture and cut injuries in case of exposure to biological factors By Siv Lise Bedringaas, Bård Sværi, Gunvor Røssland Landro, Bente Lise Lillebø og Stein Inge Stigen for The Faculty of Medicine and the section for HSE, preparedness and BHT, University of Bergen